Glenmark Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.71×	0.69×	0.75×	−39.28×	0.43×
	0.61×	0.50×	0.75×	0.06×	0.52×
	23.6%	23.5%	14.0%	5.2%	12.8%
	0.94×	0.94×	0.88×	0.70×	0.71×
	1.89×	1.89×	1.81×	1.83×	1.97×
	18.0%	14.3%	12.5%	−15.5%	4.1%
	0.0%	0.0%	12.5%	−17.3%	4.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLENMARK₹2,339.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹66,007 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.43	-39.28	0.75	0.69	0.71
Interest Burden (Pretax/EBIT) ×	0.52	0.06	0.75	0.50	0.61
EBIT Margin %	12.83	5.19	14.00	23.55	23.57
Asset Turnover ×	0.71	0.70	0.88	0.94	0.94
Financial Leverage (Assets/Equity) ×	1.97	1.83	1.81	1.89	1.89
ROE (5-step product, year-end total equity) %	4.06	-15.54	12.55	14.28	18.04
ROE (owners' profit / average owners' equity) %	4.07	-17.34	12.54	0.00	0.00

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.